24968 Federal Register / Vol. 65, No. 83 / Friday, April 28, 2000 / Notices

The extent to which the applicant

describes the facilities and resources

that are available for this program.

The extent to which applicant

describes proposed staffing, and

includes job descriptions and

curriculum vitae indicating the

applicant’s ability to carry out the

objectives of the program. Descriptions

should include the position titles,

education and experience, capabilities,

and the percentage of time each person

will devote to the program. Where

applicable, identify a state and/or

community program level coordinator(s)

who has/have the authority,

responsibility, and expertise to conduct

and manage the program.

6. Budget and Justification (Not Scored)

The extent to which the applicant

provides a detailed budget and narrative

justification consistent with the stated

objectives and planned program

activities.

7. Human Subjects (Not Scored)

The extent to which the application

adequately addresses the requirements

of Title 45 CFR part 46 for the

protection of human subjects.

H. Other Requirements

Technical Reporting Requirements

Provide CDC with original plus two

copies of

1. Semiannual progress reports;

2. Financial status report, 90 days

after the end of the budget period; and

3. Final financial status and

performance reports, no more than 90

days after the end of the project period.

Send all reports to the Grants

Management Specialist identified in the

‘‘Where To Obtain Additional

Information’’ Section of this

announcement.

The following additional

requirements are applicable to this

program. For a complete description of

each, see Attachment I.

AR–1 Human Subjects Requirements

AR–2 Requirements for Inclusion of

Women and Racial and Ethnic

Minorities in Research

AR–7 Execute Order 12372 Review

AR–8 Public Health System Reporting

Requirements

AR–9 Paperwork Reduction Act

Requirements

AR–10 Smoke-Free Workplace

Requirements

AR–11 Healthy People 2010

AR–12 Lobbying Restrictions

AR–13 Prohibition on Use of CDC

Funds for Certain Gun Control

Activities

I. Authority and Catalog of Federal

Domestic Assistance Number

This program is authorized under

section 301(a), 317(k)(2), 391, 392, 394,

and 394A [42 U.S.C. 241(a), 247b(k)(2),

280b, 280b–1, 280b–2, 280b–3] of the

Public Health Service Act, as amended.

The Catalog of Federal Domestic

Assistance number is 93.136.

J. Where To Obtain Additional

Information

This and other CDC announcements

can be found on the CDC home page on

the Internet: http://www.cdc.gov. To

receive additional written information

and to request an application kit, call 1–

888–GRANTS4 (1–888 472–6874). You

will be asked to leave your name and

address and will be instructed to

identify the Announcement number of

interest. Please refer to Program

Announcement 00090 when making

your request. If you have questions after

reviewing the content of all documents,

business management and assistance

may be obtained from: Sheryl L. Heard,

Grants Management Specialist, Grants

Management Branch, Procurement and

Grants Office, Announcement 00090,

Centers for Disease Control and

Prevention (CDC), 2920 Brandywine

Road, Suite 3000, Atlanta, GA 30341–

4146, Telephone (404) 488–2723, Email

address slh3@cdc.gov.

For program technical assistance,

contact:

Part I, Program to Increase Booster

Seat Use Among Children Riding in

Motor Vehicles. Tim W. Groza, MPA,

Centers for Disease Control and

Prevention, National Center for Injury

Prevention and Control, 4770 Buford

Highway N.E., Mailstop K63, Atlanta,

GA 30341–3724, Telephone(770) 488–

4676, Email: tgroza@cdc.gov.

Part II, Demonstration Program to

Reduce Falls Among Older Adults.

Mark Jackson, R.S., National Center for

Injury Prevention and Control, Centers

for Disease Control and Prevention,

4770 Buford Highway, NE, Mailstop

K63, Atlanta, GA 30341–3724,

Telephone (770) 488–4754, E-mail

address: mcj4@cdc.gov.

Part III, Program to Prevent Fire and

Fall-Related Injuries to Older Adults.

Pauline Harvey, MSPH, National Center

for Injury Prevention and Control,

Centers for Disease Control and

Prevention, 4770 Buford Highway, N.E.,

(K63), Atlanta, GA 30341–3724,

Telephone: (770) 488–4592, E-mail:

pdh7@cdc.gov.

Part IV, Multifaceted Teen and Young

Adult Bicycle Safety Program. Mark

Jackson, R.S., National Center for Injury

Prevention and Control, Centers for

Disease Control and Prevention, 4770

Buford Highway, NE, Mailstop K63,

Atlanta, GA 30341–3724, Telephone

(770) 488–4754, Email address:

mcj4@cdc.gov.

Part V, Multifaceted Program for the

Prevention of Dog Bite Related Injuries.

Mark Jackson, R.S., National Center for

Injury Prevention and Control, Centers

for Disease Control and Prevention,

4770 Buford Highway, NE, Mailstop

K63, Atlanta, GA 30341–3724,

Telephone (770) 488–4754, E-mail

address: mcj4@cdc.gov.

To order a copy of CDC’s

‘‘Demonstrating Your Program’s Worth:

A Primer on Evaluation for Programs to

Prevent Unintentional Injury’’;

‘‘Remembering When: A Fire and Fall

Prevention Program for Older Adults’’;

‘‘Injury Control Recommendations:

Bicycle Helmets’’; and, ‘‘A Tool Kit to

Prevent Senior Falls,’’ go to: http://

www.cdc.gov/ncipc/pub-res.

Dated: April 24, 2000.

John L. Williams,

Director, Procurement and Grants Office,

Centers for Disease Control and Prevention

(CDC).

[FR Doc. 00–10684 Filed 4–27–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Centers for Disease Control and

Prevention

Board of Scientific Counselors,

National Center for Infectious

Diseases: Addendum

Addendum

CDC is publishing this notice as a

means of further explanation of the

agenda item entitled, ‘‘Transfer of

Interstate Quarantine Authority.’’

Published in the Federal Register, April

6, 2000, Volume 65, Number 67, page

18108–18109. This item engenders a

discussion of the list of diseases for

which individuals may be apprehended,

detained, or conditionally released

pursuant to the quarantine authorities

provided in the Public Health Service

Act.

In accordance with section 361(b) of

the Public Health Service Act (42 U.S.C.

264(b)), the Board will consider and

make recommendations regarding a list

of diseases for which individuals may

be apprehended, detained, or

conditionally released in order to

prevent the introduction, transmission

or spread of such communicable disease

from foreign countries into the United

States or possession or from one state or

possesion into another.

Federal Register / Vol. 65, No. 83 / Friday, April 28, 2000 / Notices 24969

1 If the reply to the questionnaire confirms a

medical use of 4-MTA recognized by any Member

State, the substance will be subjected to a prereview

instead of a critical review.

2For Ministries of Health only.

Name: Board of Scientific Counselors,

National Center for Infectious Diseases

(NCID).

Times and Dates: 9 a.m.–5:30 p.m.,

May 4, 2000. 8:30 a.m.–2:30 p.m., May

5, 2000.

Place: CDC, Conference Room

Building 17, 1600 Clifton Road, Atlanta,

Georgia 30333.

Status: Open to the public, limited

only by the space available.

Purpose: The Board of Scientific

Counselors, NCID, provides advice and

guidance to the Director, CDC, and

Director, NCID, in the following areas:

Program goals and objectives; strategies;

program organization and resources for

infectious disease prevention and

control; and program priorities.

Matters To Be Discussed: Agenda

items will include:

1. NCID Update.

2. CDC Facilities Master Plan.

3. Laboratory Response Capacity.

4. Integrating Surveillance Systems—

NEDSS.

5. Current Issues in Vaccine

Development.

6. Tour of New Facility: Building 17.

7. Discussions.

8. Improving Communications.

9. Program Update: Mycotic Diseases.

10. Transfer of Interstate Quarantine

Authority.

11. Late Breaker: Current Scientific

Issues/Events.

12. Discussions and

Recommendations.

Other agenda items include

announcements/introductions; followup on actions recommended by the

Board December 1999; consideration of

future directions, goals, and

recommendations.

Agenda items are subject to change as

priorities dictate.

Written comments are welcome and

should be received by the contact

person listed below prior to the opening

of the meeting.

Contact Person for More Information:

Diane S. Holley, Office of the Director,

NCID, CDC, M/S C–20, 1600 Clifton

Road, NE, Atlanta, Georgia 30333,

telephone 404/639–0078.

The Director, Management Analysis

and Services office has been delegated

the authority to sign Federal Register

notices pertaining to announcements of

meetings and other committee

management activities, for both the

Centers for Disease Control and

Prevention and the Agency for Toxic

Substances and Disease Registry.

Dated: April 24, 2000.

Carolyn J. Russell,

Director, Management Analysis and Services

Office, Centers for Disease Control and

Prevention.

[FR Doc. 00–10681 Filed 4–27–00; 8:45 am]

BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Food and Drug Administration

[Docket No. 00N–1257]

International Drug Scheduling;

Convention on Psychotropic

Substances; 4-Bromo-2,5-

dimethoxyphenethylamine (2C-B);

Gamma-hydroxybutyric acid (GHB); 4-

Methylthioamphetamine (4-MTA); NMethyl-1-(3,4-methylenedioxyphenyl)-

2-butanamine (MBDB); Diazepam

(INN); Zolpidem (INN)

AGENCY: Food and Drug Administration,

HHS.

ACTION: Notice.

SUMMARY: The Food and Drug

Administration (FDA) is requesting

interested persons to submit comments

concerning abuse potential, actual

abuse, medical usefulness, and

trafficking of six drug substances. These

comments will be considered in

preparing a response from the United

States to the World Health Organization

(WHO) regarding the abuse liability and

diversion of these drugs. WHO will use

this information to consider whether to

recommend that certain international

restrictions be placed on these drugs.

This notice requesting comments is

required by the Controlled Substances

Act (CSA).

DATES: Submit written comments by

May 15, 2000.

ADDRESSES: Submit written comments

to the Dockets Management Branch

(HFA–305), Food and Drug

Administration, 5630 Fishers Lane, rm.

1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Corinne P. Moody, Center for Drug

Evaluation and Research (HFD–009),

Food and Drug Administration, 5600

Fishers Lane, Rockville, MD 20857,

301–827–1999, e-mail:

Moody@cder.FDA.gov.

SUPPLEMENTARY INFORMATION: The

United States is a party to the 1971

Convention on Psychotropic

Substances. Article 2 of the Convention

on Psychotropic Substances provides

that if a party to the convention or WHO

has information about a substance,

which in its opinion may require

international control or change in such

control, it shall so notify the Secretary

General of the United Nations and

provide the Secretary General of the

United Nations with information in

support of its opinion.

The CSA (21 U.S.C. 811 et seq.) (Title

II of the Comprehensive Drug Abuse

Prevention and Control Act of 1970)

provides that when WHO notifies the

United States under Article 2 of the

Convention on Psychotropic Substances

that it has information that may justify

adding a drug or other substances to one

of the schedules of the convention,

transferring a drug or substance from

one schedule to another, or deleting it

from the schedules, the Secretary of

State must transmit the notice to the

Secretary of Health and Human Services

(the Secretary of HHS). The Secretary of

HHS must then publish the notice in the

Federal Register and provide

opportunity for interested persons to

submit comments that will be

considered by HHS in its preparation of

the scientific and medical evaluations of

the drug or substance. The Secretary of

HHS received the following notices

from WHO:

I. WHO Notification

Ref.: C.L.1.2000

WHO questionnaire for collection of

information for review of dependenceproducing psychoactive substances.

The Director-General of the World Health

Organization presents her compliments and

has the pleasure of informing Member States

that the Thirty-second Expert Committee on

Drug Dependence (ECDD) will meet from 11

to 14 September 2000 to review the following

substances:

1. 4-Bromo-2,5-dimethoxyphenethylamine

(2C-B)

2. Gamma-hydroxybutyric acid (GHB)

3. 4-Methylthioamphetamine (4-MTA)1

4. N-Methyl-l-(3,4-methylenedioxyphenyl)-

2-butanamine (MBDB)

5. Diazepam (INN)

6. Zolpidem (INN)

One of the essential elements of the

established review procedure is for the

Secretariat to collect relevant information

from Member States to prepare a Critical

Review document for submission to the

Expert Committee on Drug Dependence. The

World Health Organization invites Member

States to collaborate, as in the past, in this

process by providing pertinent information

mentioned in the attached questionnaire2

concerning the substances listed above.

Further clarification on any of the above

items can be obtained from Quality

Assurance and Safety: Medicines (QSM),

Essential Drugs and Medicines Policy (EDM),

WHO, Geneva, to which replies should be

sent not later than 1 May 2000.